Potential conflicts of interest. M. L. reports participation on the RSV Advisory Board from Sanofi, and was paid 600 Euros. S. R. reports research project grants (payment made to the institution) from Fondazione Cr Di Firence and Sanofi Pasteur; was Principal Investigator (PI) for the European Multicentric Study (payment made to the institution) from Pfizer, co-PI for the European Multicentric Study (payment made to the institution) from Merck, Sharp & Dohme (MSD), and PI for the Italian Multicentric Study (payment was made to the institution) from Octanorm; payment was received for a presentation/educational event from MSD; payment was made to the meeting organization (9–10 December 2021) from Behring CLS. S. G. reports participation on the Zavicefta Advisory Board (8 September 2021). All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.